Literature DB >> 22171271

Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis.

Elena Y Dobrikova1, Christian Goetz, Robert W Walters, Sarah K Lawson, James O Peggins, Karen Muszynski, Sheryl Ruppel, Karyol Poole, Steven L Giardina, Eric M Vela, James E Estep, Matthias Gromeier.   

Abstract

A dependence of poliovirus on an unorthodox translation initiation mode can be targeted selectively to drive viral protein synthesis and cytotoxicity in malignant cells. Transformed cells are naturally susceptible to poliovirus, due to widespread ectopic upregulation of the poliovirus receptor, Necl-5, in ectodermal/neuroectodermal cancers. Viral tumor cell killing and the host immunologic response it engenders produce potent, lasting antineoplastic effects in animal tumor models. Clinical application of this principle depends on unequivocal demonstration of safety in primate models for paralytic poliomyelitis. We conducted extensive dose-range-finding, toxicity, biodistribution, shedding, and neutralizing antibody studies of the prototype oncolytic poliovirus recombinant, PVS-RIPO, after intrathalamic inoculation in Macaca fascicularis. These studies suggest that intracerebral PVS-RIPO inoculation does not lead to viral propagation in the central nervous system (CNS), does not cause histopathological CNS lesions or neurological symptoms that can be attributed to the virus, is not associated with extraneural virus dissemination or replication and does not induce shedding of virus with stool. Intrathalamic PVS-RIPO inoculation induced neutralizing antibody responses against poliovirus serotype 1 in all animals studied.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171271      PMCID: PMC3302279          DOI: 10.1128/JVI.06427-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Pathogenesis of poliomyelitis; reappraisal in the light of new data.

Authors:  A B SABIN
Journal:  Science       Date:  1956-06-29       Impact factor: 47.728

2.  MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus.

Authors:  Christian Goetz; Richard G Everson; Linda C Zhang; Matthias Gromeier
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

3.  Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells.

Authors:  Stephanie A Campbell; Jennifer Lin; Elena Y Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD.

Authors:  Paola Florez de Sessions; Elena Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

5.  Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

Authors:  M Gromeier; L Alexander; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

6.  Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay.

Authors:  A C Andeweg; T M Bestebroer; M Huybreghs; T G Kimman; J C de Jong
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.

Authors:  Melinda K Merrill; Matthias Gromeier
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

8.  Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76.

Authors:  Melinda K Merrill; Elena Y Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.

Authors:  Elena Y Dobrikova; Trevor Broadt; Judith Poiley-Nelson; Xiaoyi Yang; Gopalan Soman; Steve Giardina; Ray Harris; Matthias Gromeier
Journal:  Mol Ther       Date:  2008-09-02       Impact factor: 11.454

10.  NK cells recognize and kill human glioblastoma cells with stem cell-like properties.

Authors:  Roberta Castriconi; Antonio Daga; Alessandra Dondero; Gianluigi Zona; Pietro Luigi Poliani; Alice Melotti; Fabrizio Griffero; Daniela Marubbi; Renato Spaziante; Francesca Bellora; Lorenzo Moretta; Alessandro Moretta; Giorgio Corte; Cristina Bottino
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

View more
  26 in total

Review 1.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

Review 2.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.

Authors:  Michael C Brown; Jeffrey D Bryant; Elena Y Dobrikova; Mayya Shveygert; Shelton S Bradrick; Vidyalakshmi Chandramohan; Darell D Bigner; Matthias Gromeier
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

4.  Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Authors:  Annick Desjardins; Matthias Gromeier; James E Herndon; Nike Beaubier; Dani P Bolognesi; Allan H Friedman; Henry S Friedman; Frances McSherry; Andrea M Muscat; Smita Nair; Katherine B Peters; Dina Randazzo; John H Sampson; Gordana Vlahovic; William T Harrison; Roger E McLendon; David Ashley; Darell D Bigner
Journal:  N Engl J Med       Date:  2018-06-26       Impact factor: 91.245

Review 5.  Developing anti-neoplastic biotherapeutics against eIF4F.

Authors:  Jutta Steinberger; Jennifer Chu; Rayelle Itoua Maïga; Katia Sleiman; Jerry Pelletier
Journal:  Cell Mol Life Sci       Date:  2016-12-21       Impact factor: 9.261

Review 6.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 7.  The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Authors:  Russell Maxwell; Andrew S Luksik; Tomas Garzon-Muvdi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2017-06       Impact factor: 5.081

Review 8.  Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.

Authors:  Michael C Brown; Matthias Gromeier
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

9.  Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis.

Authors:  Michael C Brown; Mikhail I Dobrikov; Matthias Gromeier
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

Review 10.  Oncolytic polio virotherapy of cancer.

Authors:  Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier
Journal:  Cancer       Date:  2014-06-17       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.